A lot can happen in a year, and at n-Lorem, this past year has brought important milestones, new developments, and plenty to discuss at the upcoming 2026 Nano-rare Patient Colloquium. In this special Colloquium preview episode, Brady Huggett, editor-in-chief of Asimov Press and longtime moderator of the Colloquium’s patient experience panel, returns to sit down with n-Lorem CEO Stan Crooke. Together, they reflect on the past year, explore some of the topics likely to take center stage, and preview what attendees can expect at the 2026 Nano-rare Patient Colloquium.

Interested in attending the event? Register here.

• 2:28 – What is a day in the life of an n-Lorem research team member?
• 9:08 – How many ASOs are required to move into tolerability studies and what may cause a program to be terminated
• 12:05 – Improvements in efficiencies, bringing down costs, and growth have allowed n-Lorem to respond to the extraordinary demand
• 13:14 – Discussing the creation of individualized ASOs for two boys with SCN2A mutations and their potential to help others with the same mutation and single nucleotide variant
• 25:00 – Thoughts on the FDA’s Plausible Mechanism Framework
• 29:00 – Commercial opportunities will not alter the n-Lorem charitable arm but will provide sustainable revenues to charitably treat more patients
• 36:05 – What are the Limits of Hope and expanding those limits
• 37:54 – Empathy is an expanded sense of self, and a sphere of oneness is felt at the Colloquium

Brady Huggett is editor-in-chief of Asimov Press. He has formerly at The Transmitter and Nature Biotechnology. Brady has a B.S. in biology from Wake Forest University in Winston-Salem, North Carolina, and an M.A. in journalism from the University of North Carolina at Chapel Hill.

We cannot do
this alone

We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.